Stewart Washer
Follow
Get notifications in MyBN when activity occurs.
Stewart Washer
Co-Founder, Chair / Rumin8
Most Notable Role
A 2006 40under40 winner, Dr Stewart Washer has over 20 years of CEO and board experience, founding several biotechnology companies in both the agri-food and medical sectors.
Dr Washer was the chief executive of Calzada, founding chief executive of Phylogica, chief executive of Celentis, and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand-based life science fund and venture partner with Swiss-based Inventages Nestlé Fund.
Dr Washer held a number of board positions including as chair of iSonea, Resonance Health, Hatchtech, Cynata Therapeutics, Minomic International and Orthocell; and director of iCeutica, Immuron and AusBiotech. He was also a senator with Murdoch University.
In March 2005, Dr Washer took biotechnology company Phylogica through a successful and oversubscribed initial public offering to list on the ASX at a 30 per cent premium. Phylogica had a novel drug discovery technology based on parts of proteins derived from diverse micro-organisms that are being developed to treat stroke, diabetes, asthma and other inflammatory diseases.
Dr Washer was the chief executive of Calzada, founding chief executive of Phylogica, chief executive of Celentis, and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand-based life science fund and venture partner with Swiss-based Inventages Nestlé Fund.
Dr Washer held a number of board positions including as chair of iSonea, Resonance Health, Hatchtech, Cynata Therapeutics, Minomic International and Orthocell; and director of iCeutica, Immuron and AusBiotech. He was also a senator with Murdoch University.
In March 2005, Dr Washer took biotechnology company Phylogica through a successful and oversubscribed initial public offering to list on the ASX at a 30 per cent premium. Phylogica had a novel drug discovery technology based on parts of proteins derived from diverse micro-organisms that are being developed to treat stroke, diabetes, asthma and other inflammatory diseases.
Lists and Charts
40under40 Award Winner 2006
All 40under40 winners for 2006
| Name | Current company |
|---|
Total Shareholder Return as at 31/10/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 82nd | Botanix Pharmaceuticals | 160% | 67% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | Botanix Pharmaceuticals | $2.1m |
200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Person Activity
| NEWS: Tagged in Board Moves December 22, 2023 | 22 Dec 2023 |
| NEWS: Tagged in Board Moves November 13, 2023 | 13 Nov 2023 |
| NEW ROLE: Non-Executive Chair, Emyria | 13 Nov 2023 |
| NEW ROLE: Non-Executive Director, Orthocell | 01 Nov 2023 |
| NEWS: Tagged in Board Moves October 25, 2023 | 25 Oct 2023 |
| NEWS: Tagged in Board Moves May 29, 2023 | 29 May 2023 |
| NEW ROLE: Co-Founder, Chair, Rumin8 | 23 Jan 2023 |
| NEWS: Tagged in Advisers enjoy strong flow of listings | 20 Jan 2021 |
| NEW ROLE: Non-Executive Director, Cynata Therapeutics | 03 Nov 2020 |
| REMUNERATION UPDATE: Executive Director, Orthocell | 02 Nov 2020 |
